Pricing in the market for anticancer drugs

David H. Howard
Emory University & NBER

Peter B. Bach
Memorial Sloan Kettering

Ernst R. Berndt
MIT & NBER

Rena M. Conti
University of Chicago
Acknowledgements

• Rena M. Conti received support from the National Cancer Institute (Grant No. K07-CA138906). The opinions expressed are solely those of the authors and not that of the University of Chicago nor the National Cancer Institute.
Questions

- Have the benefit-adjusted launch prices of anticancer drugs increased over time?

- If so, why?
Outline

• The market for anticancer drugs: *not a competitive market*

• Data on pricing trends: *prices are going up, not related to benefits*

• Speculative theories on pricing behavior: *reference price models of demand and growth of discounts.*
The chemo market is interesting

• Financial significance:
  • Total spending was $37 billion in 2013 (IMS 2014)
  • 37-41% average annual growth rate 2006-2013 (Conti et al 2014)

• Symbolic significance: “Today NICE routinely denies Britons life-prolonging drugs that are deemed not ‘cost effective’… The result, studies show, is that Great Britain’s cancer survival rates are among the worst in Europe and lag behind the United States.” Newt Gingrich (2009)
  • Anticancer drugs figure prominently in national discussions of health reform, alternately symbolizing wasteful spending and biomedical progress.
Controversy over prices
“...the cost of the new generation of drugs is getting out of all proportion to the added benefit.” (Cavalli 2013). Attention has focused on a handful of high-profile drugs like bevacizumab
Some costly chemotherapeutics

• 2004: bevacizumab (Avastin), colorectal cancer, $50,000, 5 months

• 2009: sipuleucel-T (Provenge), prostate cancer, $93,000, 3 months

• 2011: ipilimumab (Yervoy), skin cancer, $120,000, 3 months
Features of the market for new chemotherapeutics

• Producers are monopolists, few close substitutes
• Insurers cover drugs for FDA-approved uses regardless of price
• Patients face low cost sharing at the margin
• Physicians make money on office-administered drugs, neutral for oral drugs
• Value left to assess by MDs, Hospitals
Patient assistance programs

We Focus on Access so You Can Focus on Health

Connecting your patients to Avastin® (bevacizumab). Welcome to Avastin Access Solutions.

I am a

- Health Care Professional
- Patient / Caregiver

Call (888) 249-4918

We are here to help. Avastin Access Solutions Support Line 6 a.m. - 5 p.m. PT, Monday through Friday.
Data

• Chemotherapy drugs approved between 1995-2013

• Price = amount paid by Medicare based on typical duration of use, stated in 2012 USD

• Survival benefit = increase in median survival time in months between treatment and control

• Other attributes: administration route, approval basis, side effects
<table>
<thead>
<tr>
<th>Approval year</th>
<th>Route IV</th>
<th>Route Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>pre-1997</td>
<td>100% of AWP</td>
<td>100% of AWP</td>
</tr>
<tr>
<td>1997-2003</td>
<td>95% of AWP</td>
<td>95% of AWP</td>
</tr>
<tr>
<td>2004</td>
<td>85% of AWP</td>
<td>85% of AWP</td>
</tr>
<tr>
<td>2005-2006</td>
<td>106% of ASP</td>
<td>106% of ASP</td>
</tr>
<tr>
<td>2006-2007</td>
<td>106% of ASP</td>
<td>Medicare price</td>
</tr>
<tr>
<td>2008-2012</td>
<td>100% of WAC</td>
<td>Medicare price</td>
</tr>
</tbody>
</table>
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval
1965 - 2013

- Monthly Price of Treatment (2013 Dollars)
- Year of FDA Approval

- Individual Drugs
- Median Monthly Price (per 5 year period)
Figure 1: Price versus gain in survival time

- **Benefit measured from RCT using OS**
- **Benefit measured from RCT using PFS**
- **Benefit measured from modeling study**

RCT: randomized controlled trial. OS: Overall survival. PFS: Progression-free survival.
Figure 2: Price per year of life gained versus approval date

The best fit line is: Price per year of life gained = $101,077 + $7,396 × Approval year.

For purposes of display, we re-coded one value from $825,000 to $500,000.

RCT: randomized controlled trial. OS: Overall survival. PFS: Progression-free survival.
Table 2: Impact of approval year and other variables on the natural logarithm of the price per year of life gained in $1,000s of 2013 USD

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval year</td>
<td>0.05 [0.02, 0.08]*</td>
<td>0.05 [0.02, 0.08]*</td>
<td>0.05 [0.02, 0.08]*</td>
<td>0.04 [0.01, 0.08]*</td>
</tr>
<tr>
<td>GI complication rate</td>
<td>0.01 [-1.11, 1.14]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutropenia rate</td>
<td>0.17 [-0.61, 0.96]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologic</td>
<td></td>
<td>0.07 [-0.30, 0.44]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiproduct firm</td>
<td></td>
<td>0.06 [-0.32, 0.44]</td>
<td></td>
<td>-0.18 [-0.59, 0.22]</td>
</tr>
<tr>
<td>Active control</td>
<td></td>
<td></td>
<td></td>
<td>0.13 [-0.32, 0.58]</td>
</tr>
<tr>
<td>Placebo control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constant</td>
<td>4.50 [4.15, 4.86]*</td>
<td>4.48 [3.92, 5.04]*</td>
<td>0.06 [-0.3, 0.4]</td>
<td>4.57 [4.17, 4.97]*</td>
</tr>
<tr>
<td>N</td>
<td>56</td>
<td>52</td>
<td>56</td>
<td>56</td>
</tr>
<tr>
<td>R-squared</td>
<td>0.15</td>
<td>0.15</td>
<td>0.16</td>
<td>0.19</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>E</th>
<th>F</th>
<th>G</th>
<th>H</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval year</td>
<td>0.05 [0.02, 0.08]*</td>
<td>0.05 [0.02, 0.08]*</td>
<td>0.05 [0.02, 0.08]*</td>
<td>0.04 [0.01, 0.07]*</td>
</tr>
<tr>
<td>Ln(competitors)</td>
<td>-0.25 [-0.48, -0.02]*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV administration</td>
<td></td>
<td>-0.16 [-0.52, 0.19]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetic test</td>
<td></td>
<td>-0.35 [-0.70, -0.01]*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second line</td>
<td></td>
<td>0.14 [-0.20, 0.48]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor deaths</td>
<td></td>
<td></td>
<td>-0.002 [-0.007, 0.002]</td>
<td></td>
</tr>
<tr>
<td>Baseline survival</td>
<td></td>
<td></td>
<td></td>
<td>0.003 [-0.006, 0.013]</td>
</tr>
<tr>
<td>Constant</td>
<td>5.00 [4.43, 5.57]*</td>
<td>4.70 [4.15, 5.24]*</td>
<td>4.58 [4.20, 4.96]*</td>
<td>4.57 [4.19, 4.95]*</td>
</tr>
<tr>
<td>N</td>
<td>56</td>
<td>56</td>
<td>56</td>
<td>53</td>
</tr>
<tr>
<td>R-squared</td>
<td>0.22</td>
<td>0.22</td>
<td>0.17</td>
<td>0.12</td>
</tr>
</tbody>
</table>

*P < 0.05, +P < 0.10
95% Confidence intervals are in brackets.
Why are benefit-adjusted prices increasing: some speculative theorizing

- Reference pricing
- Growth of discounts and rebates
Reference pricing in the chemo market

• Oncologists decide whether to use drugs

• They have no direct incentive to avoid costly drugs

• They may balk at prescribing drugs with prices they perceive as unreasonable

• Perceptions of unreasonable prices are malleable and influenced by the prices of previously approved drugs — a reference price!

• If the reference price is $X, manufacturers can set the price of a new drug at $X + \varepsilon$ without incurring a demand penalty
Demand curve w/ loss aversion

Reference price

$P$

$Q$
Least Convincing Argument of the Day

by Alex Tabarrok on December 6, 2009 at 8:29 am in Medicine | Permalink

Here is James Caruso, the chief commercial officer for drug maker Allos, defending the price of cancer drug Foltyn:

Mr. Caruso also said the price of Folotyn was not out of line with that of other drugs for rare cancers. Patients, moreover, are likely to use the drug for only a couple of months because the tumor worsens so quickly, he said.

In other words, our drug isn't so expensive given how poorly it works.
Reference pricing in the chemo market

• A spokeswoman for AstraZeneca justified the price of Irressa as “in line with other cancer treatments.” (Marcus 2004).

• The retail price of the drug will be $5,416 per month, an amount that Onyx said is in the range of similarly specialized cancer drugs. (Silber 2005)

• Gold [CEO of Dendreon] says that the cost of Provenge was based on the “overall landscape” of treatment prices for cancer. (Hutchison 2010)
Reference pricing in the chemo market

• Companies will be looking at these products to help them determine the pricing of their own drugs…Tarceva and other drugs will likely take their cue from Erbitux and Avastin. --Wall St. Analyst

• …the market structure effectively provides no mechanism for price control in oncology other than companies’ goodwill and tolerance for adverse publicity --Wall St. Analyst
Reference pricing in the chemo market

• Right now…it is basically chutzpah…The most powerful predictor of the entry price is the entry price of the drug that came before it. There is nothing to do with innovation, accelerated approval, number of patients served. It is just a game of chicken. -- Oncologist
Reference pricing and Zaltrap

The New York Times

October 14, 2012

In Cancer Care, Cost Matters
By PETER B. BACH, LEONARD B. SALTZ and ROBERT E. WITTES

At Memorial Sloan-Kettering Cancer Center, we recently made a decision that should have been a no-brainer: we are not going to give a phenomenally expensive new cancer drug to our patients.

The reasons are simple: The drug, Zaltrap, has proved to be no better than a similar medicine we already have for advanced colorectal cancer, while its price — at $11,063 on average for a month of treatment — is more than twice as high.

In most industries something that offers no advantage over its competitors and yet sells for twice the price would never even get on the market. But that is not how things work for drugs. The Food and Drug Administration approves drugs if they are shown to be “safe and effective.” It does not consider what the relative costs might be once the new medicine is marketed.

By law, Medicare must cover every cancer drug the F.D.A. approves. (A 2003 law, moreover, mandates payment at the price the manufacturers charge, plus a 6 percent cushion.) In most states private insurers are held to this same standard. Physician guideline-setting organizations likewise focus on whether or not a treatment is effective, and rarely factor in cost in their determinations.

Ignoring the cost of care, though, is no longer tenable. Soaring spending has presented the medical community with a new obligation. When choosing treatments for a patient, we have to consider the financial strains they may cause alongside the benefits they might deliver.

This is particularly the case with cancer, where the cost of drugs, and of care over all, has risen precipitously. The typical new cancer drug coming on the market a decade ago cost about $4,500 per month (in 2012 dollars); since 2010 the median price has been around $10,000. Two of the new cancer drugs cost more than $35,000 each per month of treatment.

The burden of this cost is borne, increasingly, by patients themselves — and the effects can be devastating. In 2006, one-quarter of cancer patients reported that they had used up all or most of their savings paying for care; a study last year reported that 2 percent of cancer patients were driven into bankruptcy by
Discounts and rebates are significant

Adapted from a slide by Safety Net Hospitals for Pharmaceutical Access
Source: Data derived from Prices for Brand-Name Drugs Under Selected Federal Programs, Congressional Budget Office (June 2005)
Beneficiaries (Millions)

Source: CMS, Medicare and Medicaid statistical supplements
340B drug pricing program is growing

Growth in the Number of Participating 340B Covered Entities (1998-2013)

Source: Avalere Health analysis of Health Resources and Services Administration Office of Pharmacy Affairs files.
• Consolidation shifts bargaining
• GPO power may increase

The number of new molecular entities launched in 2013 is the highest in the last 10 years.
2014 Growth Rates By Selected Sector, Before And After The Impact Of The Affordable Care Act

Cuckler G A et al. Health Aff 2013;32:1820-1831
Conclusions

• Benefit- and inflation-adjusted launch prices have increased

• Two plausible explanations
  • Demand is subject to reference-price effects
  • Growth of discounts and rebates

• These tradeoffs are not going to go away soon